Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9019698 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL30775720 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL30775787 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL29355417 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL1659938 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL30775723 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL18746282 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL460038 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL1659934 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL1660720 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488010-B1 | MANIPULATION OF FLAVONOID BIOSYNTHETIC PATHWAY | AGRICULTURE VICTORIA SERV PTY (AU) | 2017-12-06 | — | — | EP | disclosed |
| US-20160138034-A1 | Novel Genes Involved In Biosynthesis | GRASSLANZ TECHNOLOGY LIMITED (NZ) | 2016-05-19 | — | — | US | disclosed |
| US-9200292-B2 | MYB14 sequences and uses thereof for flavonoid biosynthesis | GRASSLANZ TECHNOLOGY LIMITED (NZ) | 2015-12-01 | — | — | US | disclosed |
| US-9187448-B2 | Flavonoid compounds | CARDERO THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187448-B2 | Flavonoid compounds | CARDERO THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9051380-B2 | MYB14 sequences and uses thereof for flavonoid biosynthesis | GRASSLANZ TECHNOLOGY LIMITED (NZ) | 2015-06-09 | — | — | US | disclosed |
| EP-2294200-B1 | NOVEL GENES INVOLVED IN BIOSYNTHESIS | GRASSLANZ TECHNOLOGY LTD (NZ) | 2015-03-04 | — | — | EP | disclosed |
| US-20140256741-A1 | FLAVONOID COMPOUNDS | CARDERO THERAPEUTICS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256741-A1 | FLAVONOID COMPOUNDS | CARDERO THERAPEUTICS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013022846-A2 | FLAVONOID COMPOUNDS | CARDERO THERAPEUTICS, INC. (US) | 2013-02-14 | — | — | WO | disclosed |
| US-8273950-B2 | Polynucleotides encoding phenylpropanoid and flavonoid biosynthetic pathway enzymes in coffee | NESTEC S. A. (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20120204289-A1 | Manipulation of flavonoid biosynthetic pathway | AGRICULTURE VICTORIA SERVICES PTY LTD. (AU) | 2012-08-09 | — | — | US | disclosed |
| US-20120066792-A1 | Novel Genes Involved In Biosynthesis | GRASSLANZ TECHNOLOGY LIMITED (NZ) | 2012-03-15 | — | — | US | disclosed |
| US-20110179528-A1 | NOVEL GENES INVOLVED IN BIOSYNTHESIS | GRASSLANZ TECHNOLOGY LIMITED (NZ) | 2011-07-21 | — | — | US | disclosed |
| EP-2294200-A1 | NOVEL GENES INVOLVED IN BIOSYNTHESIS | Grasslanz Technology Limited (NZ) | 2011-03-16 | — | — | EP | disclosed |
| US-20100037357-A1 | Polynucleotides Encoding Phenylpropanoid and Falvonoid Biosynthetic Pathway Enzymes in Coffee | NESTEC S.A. (CH) | 2010-02-11 | — | — | US | disclosed |
| WO-2009148336-A1 | NOVEL GENES INVOLVED IN BIOSYNTHESIS | GRASSLANZ TECHNOLOGY LIMITED (NZ) | 2009-12-10 | — | — | WO | disclosed |
| EP-1937803-A2 | POLYNUCLEOTIDES ENCODING PHENYLPROPANOID AND FLAVONOID BIOSYNTHETIC PATHWAY ENZYMES IN COFFEE | Cornell University (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007044992-A2 | POLYNUCLEOTIDES ENCODING PHENYLPROPANOID AND FLAVONOID BIOSYNTHETIC PATHWAY ENZYMES IN COFFEE | CORNELL UNIVERSITY (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110179528-A1 | NOVEL GENES INVOLVED IN BIOSYNTHESIS | MYB, MYBBP1A, PHAX | CYP3A4 2756/4885KDM4E 295/4885HSD17B10 3563/4885 |
| US-20120066792-A1 | Novel Genes Involved In Biosynthesis | MYB, MYBBP1A, PHAX | CYP3A4 2756/4885KDM4E 295/4885HSD17B10 3563/4885 |
| US-20140256741-A1 | FLAVONOID COMPOUNDS | FIS1, TFAM, MFN2 | CYP3A4 3740/4885KDM4E 1854/4885HSD17B10 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.